Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA test may help doctors personalize heart failure treatment

NCT ID NCT07054489

Knowledge-focused Sponsor: David Lanfear Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study explores whether a person's genetic makeup can guide how doctors prescribe beta-blockers for heart failure with mildly reduced pumping ability. Ten participants will receive beta-blocker therapy guided by their polygenic score, and researchers will measure changes in heart function using MRI. The goal is to see if genetics can make treatment more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
beta blocker
What this could lead to
If successful, this could show that genetic testing helps doctors choose the right dose of beta-blocker for heart failure patients, leading to more personalized treatment.
What could go wrong
This is a very small early study with only 10 participants, so results may not apply to everyone. It is testing a method, not a new drug, so it won't directly improve health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-89 years * Ejection Fraction (EF) \>40% and =\<50% by any modality within 1 year (must be most recent) * Clinical diagnosis of HF within 1 year, evidenced by any one: Hospital discharge with primary or secondary HF diagnosis, ER discharge with primary diagnosis of HF, ambulatory diagnostic code for HF and diuretic use, BNP\>35 ng/L or NTproBNP \>125 ng/L at any time * Expected ability to fully participate in study (can tolerate study processes, no long travel) Exclusion Criteria: * Unable to provide informed consent * Previous documented EF =\< 35% * Currently on BB =\>25% target dose * Uncontrolled hypertension (systolic BP \> 180 at enrollment) * Has contraindications to all BB or intolerance to metoprolol * Systolic BP \< 100 or heart rate \<70 * Current cancer requiring active treatment * Heart transplant or LVAD or expected in the next year * Life expectancy \< 1 year for any reason * Dialysis dependence or ESRD * MI/ PCI or other cardiac surgery within 90 days prior to enrollment or planned in the future * Absolute indication for BB other than heart failure (e.g. tachyarrhythmia required BB for rate control, angina) * If PI decides for any reason participation in trial is not in best interest of the patient * Has a contraindication to completing MRI procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Polygenic score

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Henry Ford Health

    RECRUITING

    Detroit, Michigan, 48202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.